132 related articles for article (PubMed ID: 23422925)
1. Effect of quercetin on P-glycoprotein transport ability in Chinese healthy subjects.
Wang SY; Duan KM; Li Y; Mei Y; Sheng H; Liu H; Mei X; Ouyang W; Zhou HH; Liu ZQ
Eur J Clin Nutr; 2013 Apr; 67(4):390-4. PubMed ID: 23422925
[TBL] [Abstract][Full Text] [Related]
2. Lack of effect of continuous glycyrrhizin administration on the pharmacokinetics of the P-glycoprotein substrate talinolol in healthy volunteers.
Yan M; Fang PF; Li HD; Xu P; Liu YP; Wang F; Cai HL; Tan QY
Eur J Clin Pharmacol; 2013 Mar; 69(3):515-21. PubMed ID: 22983284
[TBL] [Abstract][Full Text] [Related]
3. MDR1 genotype do not influence the absorption of a single oral dose of 100 mg talinolol in healthy Chinese males.
Zhang WX; Chen GL; Zhang W; Tan ZR; Liu J; Zhou G; Hu DL; Zhou HH
Clin Chim Acta; 2005 Sep; 359(1-2):46-52. PubMed ID: 16170863
[TBL] [Abstract][Full Text] [Related]
4. Effect of single-dose and short-term administration of quercetin on the pharmacokinetics of talinolol in humans - Implications for the evaluation of transporter-mediated flavonoid-drug interactions.
Nguyen MA; Staubach P; Wolffram S; Langguth P
Eur J Pharm Sci; 2014 Sep; 61():54-60. PubMed ID: 24472704
[TBL] [Abstract][Full Text] [Related]
5. Grapefruit juice ingestion significantly reduces talinolol bioavailability.
Schwarz UI; Seemann D; Oertel R; Miehlke S; Kuhlisch E; Fromm MF; Kim RB; Bailey DG; Kirch W
Clin Pharmacol Ther; 2005 Apr; 77(4):291-301. PubMed ID: 15903127
[TBL] [Abstract][Full Text] [Related]
6. Unexpected effect of concomitantly administered curcumin on the pharmacokinetics of talinolol in healthy Chinese volunteers.
Juan H; Terhaag B; Cong Z; Bi-Kui Z; Rong-Hua Z; Feng W; Fen-Li S; Juan S; Jing T; Wen-Xing P
Eur J Clin Pharmacol; 2007 Jul; 63(7):663-8. PubMed ID: 17468862
[TBL] [Abstract][Full Text] [Related]
7. MDR1 genotypes do not influence the absorption of a single oral dose of 600 mg valacyclovir in healthy Chinese Han ethnic males.
Zhang Y; Jiang XH; Hu YQ; Li ZR; Su L; Wang ZG; Ma G
Br J Clin Pharmacol; 2008 Aug; 66(2):247-54. PubMed ID: 18460034
[TBL] [Abstract][Full Text] [Related]
8. Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers.
Han Y; Guo D; Chen Y; Tan ZR; Zhou HH
Xenobiotica; 2009 Sep; 39(9):694-9. PubMed ID: 19555315
[TBL] [Abstract][Full Text] [Related]
9. CYP3A5*3 and MDR1 C3435T are influencing factors of inter-subject variability in rupatadine pharmacokinetics in healthy Chinese volunteers.
Xiong Y; Yuan Z; Yang J; Xia C; Li X; Huang S; Zhang H; Liu M
Eur J Drug Metab Pharmacokinet; 2016 Apr; 41(2):117-24. PubMed ID: 25427746
[TBL] [Abstract][Full Text] [Related]
10. ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.
Zhou Q; Ruan ZR; Yuan H; Xu DH; Zeng S
Pharmazie; 2013 Feb; 68(2):129-34. PubMed ID: 23469685
[TBL] [Abstract][Full Text] [Related]
11. No effect of MDR1 C3435T polymorphism on oral pharmacokinetics of telmisartan in 19 healthy Chinese male subjects.
Guo X; Chen XP; Cheng ZN; Luo X; Guo R; Chen L; Chen J; Chen B; Peng J; Li YJ
Clin Chem Lab Med; 2009; 47(1):38-43. PubMed ID: 19072027
[TBL] [Abstract][Full Text] [Related]
12. CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T are determinants of inter-subject variability in fluvastatin pharmacokinetics in healthy Chinese volunteers.
Zhou Q; Ruan ZR; Yuan H; Zeng S
Arzneimittelforschung; 2012 Nov; 62(11):519-24. PubMed ID: 22941809
[TBL] [Abstract][Full Text] [Related]
13. Effect of genistein on the activities of cytochrome P450 3A and P-glycoprotein in Chinese healthy participants.
Xiao CQ; Chen R; Lin J; Wang G; Chen Y; Tan ZR; Zhou HH
Xenobiotica; 2012 Feb; 42(2):173-8. PubMed ID: 21943317
[TBL] [Abstract][Full Text] [Related]
14. Effects of curcumin on the pharmacokinetics of talinolol in human with ABCB1 polymorphism.
He X; Mo L; Li ZY; Tan ZR; Chen Y; Ouyang DS
Xenobiotica; 2012 Dec; 42(12):1248-54. PubMed ID: 22725663
[TBL] [Abstract][Full Text] [Related]
15. CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics.
Zhou Q; Chen QX; Ruan ZR; Yuan H; Xu HM; Zeng S
Pharmazie; 2013 Mar; 68(3):187-94. PubMed ID: 23556337
[TBL] [Abstract][Full Text] [Related]
16. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol.
Siegmund W; Ludwig K; Giessmann T; Dazert P; Schroeder E; Sperker B; Warzok R; Kroemer HK; Cascorbi I
Clin Pharmacol Ther; 2002 Nov; 72(5):572-83. PubMed ID: 12426521
[TBL] [Abstract][Full Text] [Related]
17. High-dose short-term administration of naringin did not alter talinolol pharmacokinetics in humans.
Nguyen MA; Staubach P; Tamai I; Langguth P
Eur J Pharm Sci; 2015 Feb; 68():36-42. PubMed ID: 25486333
[TBL] [Abstract][Full Text] [Related]
18. Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects.
Choi JH; Lee YJ; Jang SB; Lee JE; Kim KH; Park K
Br J Clin Pharmacol; 2007 Aug; 64(2):185-91. PubMed ID: 17391324
[TBL] [Abstract][Full Text] [Related]
19. Effects of Ginkgo biloba extract ingestion on the pharmacokinetics of talinolol in healthy Chinese volunteers.
Fan L; Tao GY; Wang G; Chen Y; Zhang W; He YJ; Li Q; Lei HP; Jiang F; Hu DL; Huang YF; Zhou HH
Ann Pharmacother; 2009 May; 43(5):944-9. PubMed ID: 19401473
[TBL] [Abstract][Full Text] [Related]
20. Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol.
Schwarz UI; Hanso H; Oertel R; Miehlke S; Kuhlisch E; Glaeser H; Hitzl M; Dresser GK; Kim RB; Kirch W
Clin Pharmacol Ther; 2007 May; 81(5):669-78. PubMed ID: 17392718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]